Fungal infections following solid-organ transplantation remain a major cause of morbidity and death. Their incidence ranges from 5% among recipients of kidney transplants to as high as 40% among recipients of liver transplants. Species of Candida and Aspergillus account for more than 80% of fungal episodes. Moreover, more than 80% of fungal infections occur within the first 2 months after transplantation, with a resulting mortality of 30%-100%. The pathogenesis of infection and the risk factors involved depend on the type of transplant and the infecting microor ganism. Cyclosporine has not significantly reduced the incidence or severity of fungal infections in this population. The value of surveillance cultures and fungal antigen detection in solid-organ transplant recipients remains to be determined. Amphotericin B is still a first-line drug, but its potential nephrotoxicity makes its use problematic, especially in renal transplant recipients. Fluconazole is a potential alternative for the treatment of infections due to Candida species and Cryptococcus neoformans. The role of antifungal compounds in the prophylaxis of fungal infec tion in recipients of solid-organ transplants needs to be established.
Fungal infections following solid-organ transplantation remain a major cause of morbidity and death. Their incidence ranges from 5% among recipients of kidney transplants to as high as 40% among recipients of liver transplants. Species of Candida and Aspergillus account for more than 80% of fungal episodes. Moreover, more than 80% of fungal infections occur within the first 2 months after transplantation, with a resulting mortality of 30%-100%. The pathogenesis of infection and the risk factors involved depend on the type of transplant and the infecting microor ganism. Cyclosporine has not significantly reduced the incidence or severity of fungal infections in this population. The value of surveillance cultures and fungal antigen detection in solid-organ transplant recipients remains to be determined. Amphotericin B is still a first-line drug, but its potential nephrotoxicity makes its use problematic, especially in renal transplant recipients. Fluconazole is a potential alternative for the treatment of infections due to Candida species and Cryptococcus neoformans. The role of antifungal compounds in the prophylaxis of fungal infec tion in recipients of solid-organ transplants needs to be established.
Solid-organ transplantation is now a therapeutic option in many human diseases. The quality of life and the rates of survival after organ transplantation have greatly improved as a result o f advances in surgical techniques, immunosuppres sive therapy, and medical management of patients. How ever, complications such as infection and allograft rejection remain major causes of morbidity and death. O f the different types o f severe infection following solid-organ transplanta tion, those caused by fungi carry the highest mortality de spite having a lower incidence than bacterial or viral infec tions. Possible explanations are (1) the difficulty o f early diagnosis together with a low index o f suspicion; (2) a lack of effective therapy in infections caused, for example, by Asper gillus species; (3) the difficulties encountered in the use of certain antifungal drugs because o f their toxicity or interac tion with immunosuppressive drugs, such as cyclosporine; and (4) the limited data on effective antifungal prophylactic regimens in solid-organ transplantation.
Fungal infections in the different types o f solid-organ transplantation have different underlying pathogenetic mech anisms and modes o f clinical presentation. However, the common features o f these infections in all solid-organ recipi ents distinguish them from fungal infections in other types of immunocompromised patients, such as recipients o f bone marrow transplants or neutropenic patients. The incidence, characteristics, and risk factors of severe fungal infections in various types of solid-organ transplantation have been de scribed for individual organ programs and centers, but a re port summarizing the features of these infections in solid-or gan transplantation has been lacking. Furthermore, despite significant advances in the diagnosis, prophylaxis, and treat ment o f severe fungal infections in immunocompromised pa tients, the evaluation and application of newer diagnostic techniques and antifungal agents in the management of solid-organ recipients have lagged behind. Because of the great impact of severe fungal infections on morbidity and mortality in this population, it seems worthwhile to summa rize our current knowledge of this topic and to delineate di rections that may be taken in the future with respect to fun gal infections following solid-organ transplantation. most bacterial infections, develops early after transplanta tion (median, 23 days), while candidal infection occurs later (median, 44 days) [3] . A constant finding, common to all types o f solid-organ transplants, is the almost universally fa tal outcome o f aspergillus infection despite treatm ent with amphotericin B [3, 23] .
Heart-lung and lung transplantation. Recipients of com bined heart-lung transplants or o f lung transplants alone de velop fungal infection at a higher rate than do recipients of heart transplants alone; rates were 22% and 5%, respectively, in one series from the same institution [4] , and the overall incidences range for both groups from 15% to 35% [6, 7] (table 1). Most infections are caused by Candida species (60%-100%). Other frequent causes are Aspergillus species (20%-27%) and Cryptococcus neoformans (19%-20%) [4, 6, 7] . Not uncommonly, aspergillus infection can occur con comitantly with candidal infection (range, 22-77 days) [4, 7] during the early to intermediate posttransplantation period, although aspergillus infection usually presents later (9-90 days after transplantation) [7] . Candidal infection after heart or heart-lung transplantation may be a cause of sudden death resulting either from rupture o f the aortic anastomosis sec ondary to mycotic aneurysm [24] or from mediastinal ab scesses secondary to dehiscence o f airway anastomosis [7] . The overall mortality o f fungal infection in heart-lung and lung transplant recipients ranges between 40% and 70% [4, 6, 7] . Donor organs are potential sources of posttransplantation pathogens, and lungs can be a reservoir o f pathogenic fungi (dimorphic fungi and C. neoformans). However, infection with these organisms has seldom been described after lung transplantation [4, 6, 7] . The few cases o f cryptococcal infec tion in one series o f heart-lung and lung transplant recipients were thought to be related to inhalation o f the organisms after transplantation [7] .
Liver transplantation. Orthotopic liver transplant recipi ents-together with pancreas transplant recipients-have a higher incidence o f severe fungal infection (especially that due to Candida) than do recipients o f other types o f solid-or gan transplants [10, 12] . The incidence ranges between 4% and 50% [8-12, 25, 26] , with fungal infections accounting for 20%-30% o f all severe infections in most series [8, 11, 25, 27] (table 1) . The clinical presentation differs from that de scribed in heart or heart-lung recipients in that there is a higher incidence of intraabdominal infections (intraabdom inal abscesses, peritonitis) that subsequently disseminate. In one large series 52% of fungal episodes were either intraab dominal or disseminated, while only 16% of episodes were localized to the lungs [11] . This higher incidence of intraab dominal infection correlated with the microbiology of fungal infection in these patients: Candida species caused 88.5% of infections and Aspergillus species caused 14% [16] . Similar Candida-io-Aspergillus ratios have been noted in other series [8-10, 25, 27] . Most fungal infections (85%-100% of epi sodes) develop within the first 2 months after liver transplan tation, with high mortality (50%-77%) overall; 100% in aspergillus infection) [8, 10, 11] . As in heart and heart-lung transplantation, many of these infections are diagnosed post mortem [ 11] .
Pancreatic transplantation. Pancreatic transplantation is becoming a therapeutic alternative for diabetic patients. The number o f recipients and the number o f medical centers per forming this type of transplantation are still lower than the corresponding figures for other types of solid-organ trans plantation; therefore, reports o f infectious complications are sparse. Two special features of pancreatic transplantation in fluencing the development o f fungal infection are underlying diabetic disease and the fact that the pancreas is occasionally transplanted into patients with functioning renal grafts who are already immunosuppressed. As expected, posttransplan tation morbidity and complication rates are higher in com bined pancreas-kidney transplantation than in kidney trans plantation alone [28] . O f a series of 98 patients who underwent a total of 116 pancreatic transplantations (per formed by different surgical techniques), 26 (27%) developed intraabdominal infections of all etiologies [14] . Infection with Candida species was associated with 10 (38%) of these episodes, and enteric drainage was the surgical technique fol lowed by the highest incidence. Infection-related mortality was 27%, though the precise contribution o f fungal infection is unclear [14] . Intraabdominal infection led to removal of the graft in 18 o f the 26 patients and resolved without graft removal in 5. In a smaller series o f 16 cases o f pancreatic transplantation (all performed by bladder drainage), three patients (19%) developed severe fungal infection [13] . The only fungal organism isolated in this series was Candida spe cies, and the clinical presentations consisted o f fungemia (one case) and deep abdominal wound infection requiring surgical debridement (two cases). No deaths related to fungal infection were reported in these series [13] . A constant fea ture o f candidal infection in these patients was the high inci dence o f urinary tract colonization [13] . The relevance and role o f such colonization in subsequent dissemination re main to be studied.
Renal transplantation. Renal transplantation is presently associated with the lowest incidence o f fungal infection o f all solid-organ transplantation procedures: fungi account for ~5% o f all infections in renal transplant recipients [29] . Three decades ago, 50% of deaths in this population were associated with this type o f infection [30] . Candida species, Aspergillus species, and C. neoformans are most frequently isolated, although nearly all other types o f fungal infection have also been described [31] [32] [33] [34] [35] . The urinary tract is the most common site o f fungal infections (especially those caused by Candida)-a feature that distinguishes renal from other types o f transplantation [29, [36] [37] [38] . Candidal infec tions may appear at any time throughout the postoperative period but are most frequent during the initial 6 months [37] . The clinical presentation is mainly one o f fungemia asso ciated with urinary tract infection, catheter-related sepsis, or esophagitis [29] . Aspergillus and Cryptococcus cause opportu nistic infections during the early and later posttransplanta tion periods [37] . Aspergillus infection affects primarily the lungs (with occasional dissemination) and the CNS. Aspergil lus, Cryptococcus, and Listeria monocytogenes account for three-quarters o f all infections of the CNS in kidney recipi ents [37, 39] .
Aspergillus infection carries the highest associated mortal ity in this population [30, 31, 40, 41] . In fact, the overall mortality from aspergillus infection has been 100% in large series o f solid-organ transplant recipients. However, excep tions have been described in isolated case reports. In addi tion, the prognosis in aspergillus infection may differ with the infecting species. For example, in our liver transplanta tion program, we have successfully used a surgical and medi cal approach to treat pulmonary infection due to Aspergillus terreus but have been unsuccessful in curing infection due to Aspergillus fumigatus.
Pathogenesis
The pathogenesis o f fungal infections in solid-organ trans plant recipients is incompletely understood. Underlying mechanisms depend on the type o f fungus, the type o f trans plant, the surgical technique, underlying metabolic defects, and specific immunosuppression. Aspergillus infection is ac quired mainly by the inhalation of spores. Several nosoco mial infections in solid-organ recipients have been associated with construction work in the immediate hospital area and with contaminated ventilation systems [3, [42] [43] [44] [45] [46] . Alveolar macrophages (inhibited by the administration of steroids) normally suppress the germination of inhaled spores, while functioning neutrophils eliminate residual hyphae (reviewed in [47] ). Thus, both the neutropenia and the dysfunction of neutrophils and macrophages that are often documented in solid-organ transplant recipients favor the development of aspergillosis. Cell-mediated immunity, which is also affected by immunosuppressive therapy, plays a major role (together with macrophage-neutrophil function) in defense against candidal infections [48, 49] . Furthermore, conditions lead ing to increased candidal colonization, such as treatment with antibiotics, use of indwelling bladder or intravenous catheters, and disruption of the intestinal mucosa by surgical transplantation procedures, profoundly affect the pathogene sis of infection due to Candida species. Since most cases of candidiasis arise from endogenous sources, substantial ef forts are made to eliminate or decrease the degree of coloni zation in solid-organ recipients. For example, heart-lung transplant recipients have a high incidence of candidal col onization o f tracheal and bronchial secretions; this condition probably originates from the donor trachea. Measures reduc ing such colonization result in a decreased incidence of se vere candidal infections [8] . Likewise, colonization of the gastrointestinal tract is a potential source o f intraabdominal or disseminated infection in those patients whose organ transplantation surgery requires disruption of the intestinal mucosa (i.e., those undergoing orthotopic hepatic or pancre atic transplantation). The donor duodenal segment is fre quently colonized with Candida [50] and thus is a possible source of infection for both liver and pancreas recipients.
In the case of pancreatic transplantation, pancreatic exo crine secretions into the bowel are potential sources of infec tion with enteric flora [51, 52] and serve as a good culture medium for certain microorganisms [53] . This situation could explain the high incidence of urinary candidal coloni zation in pancreas recipients, whose pancreatic exocrine se cretions drain into the bladder, creating a nonacidic environ ment that favors candidal colonization [13] . However, this possible effect may be difficult to disentangle from the role played by indwelling bladder catheters. The defective killing o f C. albicans by granulocytes in diabetic patients [54] aggra vates the problem. Therefore, pancreatic transplant recipi ents are highly susceptible to candidal infection [31] .
In liver transplantation, surgery disrupts the biliary tract and small bowel, allowing the release of Candida microorgan isms [10] . Fungal translocation across the intestinal mucosa is also a source o f endogenous contamination [55] [56] [57] . In experimental models, obstructive jaundice is associated with increased candidal dissemination [58] . Antifungal prophy laxis apparently lowers the incidence o f candidal infection by decreasing colonization o f the gut at the time of liver transplantation [59] .
Catheter-related sepsis is a common presentation of fungal infection in recipients o f solid-organ transplants. Once more, the data available on this topic are mainly for neutropenic recipients of bone marrow, in whom the underlying risk fac tors for development o f catheter-related sepsis may be some what different from those affecting solid-organ transplant re cipients. Prolonged periods o f neutropenia and long-term indwelling central venous catheterization are unusual in the latter group. Catheter-related sepsis of fungal etiology (Can dida species) in solid-organ recipients is most often asso ciated with prolonged hospitalization (especially in intensive care units) and originates from short central venous catheters rather than from Hickman catheters. As in other types of immunocompromised patients [60] [61] [62] , management should include prompt removal o f the suspect catheter and antifungal therapy with amphotericin B or fluconazole.
The significance o f fungemia in solid-organ transplant re cipients also remains to be studied. Candidemia in immuno compromised patients is associated with mortality of >50% [63] [64] [65] . Prompt initiation of antifungal therapy has im proved the outcome o f fungemia in some studies [63, 64] . In others the outcome o f candidemia has been the same with or without treatm ent [66] . (The promptness with which therapy is initiated may play a significant role in the differences ob served among these studies.) The clinical relevance of in vi tro susceptibility testing o f Candida isolates from the blood remains unknown. Blood isolates for which MICs o f ampho tericin B are >0.8 /ig/mL are associated with higher mortality [67, 68] . The use o f liposomal amphotericin B or fluconazole in the treatment o f fungemia involving " resistant" isolates warrants further study. Because candidemia in immunocom promised individuals can involve not only C. albicans but also Candida krusei or Candida tropicalis [69], therapy with fluconazole (which is relatively inactive against C. krusei) should not be started unless the fungus has been identified. Surveillance cultures [70] may be useful in decisions about whether to start antifungal therapy for certain types of candi dal infections. A single episode o f fungemia should not be disregarded because it is considered to represent transient colonization or contamination. In one study of immunocom promised patients (not solid-organ recipients), fungemia doc umented by a single isolate o f Candida species carried the same prognosis as fungemia documented by multiple posi tive blood cultures [69] . Again, relevant information is lack ing for the solid-organ recipient population, and information for other immunocompromised patients must therefore serve as a general guideline.
Risk Factors
Identification of specific risk factors predisposing to fungal infection in solid-organ recipients is of critical importance.
This information would facilitate the selective targeting of certain patients for specific prophylaxis, thereby reducing the incidence of fungal infection and its resultant morbidity and mortality. In several studies of bone-marrow transplant recip ients, risk factors for severe fungal infections have been iden tified [71] [72] [73] . Such information is not widely available for solid-organ recipients other than those undergoing ortho topic liver transplantation, in whom the following risk fac tors were identified by means of univariate statistical analy sis: preoperative administration of steroids and antibiotics, prolonged duration of surgery, administration of steroid bo luses for the treatment of allograft rejection during the first 2 months after transplantation, and prolonged antibiotic use after transplantation [10] . In a study of 101 liver transplant recipients, all 18 fungal episodes (14 caused by Candida) developed in patients whose duration of surgery was >12 hours and who received prolonged antibiotic therapy afterbut not before-transplantation [8] . In another study of 42 liver transplant recipients, additional risk factors were identi fied for the 9 cases of severe fungal infection: high preopera tive serum albumin level, biliary atresia, prolonged mean time in the intensive care unit after transplantation, gastroin testinal or vascular complications, age of > 20 years, and he modialysis after transplantation [25] . In yet another study of risk factors, 355 liver transplantations were analyzed; 91 fungal infections developed in 72 patients [11] . By univar iate analysis, 23 risk factors (out of a possible 38 pre-, intra-, and posttransplantation factors) were identified. These in cluded some factors already mentioned. However, this study provided novel confirmatory data obtained by multivariate analysis. O f the 23 variables identified as significant by means of univariate analysis, only the following were also identified in the multivariate analysis: retransplantation, reintubation, urgent clinical status at the time of transplanta tion, high risk score, requirement for intraoperative transfu sion, method of biliary reconstruction, steroid use after transplantation, bacterial infections after transplantation, an tibiotic use after transplantation, and vascular complications [in. Since the majority (88.5%) of fungal infections were caused by Candida species, these risk factors are probably applicable mainly to the development of candidiasis.
In other types of solid-organ transplantation, extensive studies of risk factors are lacking. Prolonged antibiotic use favors the development of fungal infection in heart-lung transplant recipients [4] , as do bacterial infections in heart recipients [3] and antirejection treatment and underlying diabetes mellitus in kidney recipients [31] . These identified risk factors contrast with those in other immunocompro mised patients; for example, in leukemic patients undergoing bone marrow transplantation, the duration of neutropenia is a primary risk factor for infections due to Aspergillus and Candida [69, [71] [72] [73] .
Immunosuppressive therapy. The immunosuppressive therapy that has been administered may be a possible addi tive risk factor for fungal infection. Since the introduction of cyclosporine, survival after and outcome o f solid-organ transplantation have significantly improved [74, 75] . How ever, it is still uncertain whether these improvements are due to a decrease in the incidence of severe infection, especially fungal infection. A review of 10 series o f cases (nine consist ing of kidney recipients and one consisting o f heart recipi ents) indicated that, compared with azathioprine and prednisone with or without antithymocyte globulin or anti lymphocyte globulin, cyclosporine results in a lower inci dence of bacterial and viral infections but not o f fungal infec tions [76] . Heart transplant recipients treated with cyclosporine-compared with matched controls given a con ventional regimen o f azathioprine, prednisone, and antithy mocyte globulin-had an overall reduction in the rates of bacterial, viral, and protozoan infections as well as in infec tion-related mortality. However, no statistically significant difference in the incidence o f fungal infections (all caused by Aspergillus and Candida) was found [3] . Results have been similar in other studies o f heart transplantation [15, 16, 77] .
M uromonab-CD3 is currently being used as a prophylac tic immunosuppressive agent. Preliminary reports have not documented an increase in fungal infection with its use [17] . [18, 19, 71] and in animal models [20, 21 ] and therefore may be an added risk factor for fungal infection. Measures reducing the incidence of CMV infections after transplantation may indirectly reduce the in cidence of fungal infections as well. Studies in which prophy laxis with immunoglobulin is given in an attem pt to reduce the incidence o f CMV infection show a decrease in the rate of fungal infection among bone marrow and kidney recipi ents [22, 78] . W hether this decrease is due to a decrease in the rate of some forms of CMV infection (as seen in these studies) or to an effect (direct or indirect) of 7 -globulin on fungal infection remains unknown. Studies of prophylaxis with antiviral compounds that decrease the incidence of CMV infections have not yet addressed the issue of possible reductions in the incidence o f other opportunistic infections, such as those caused by fungi.
Infection with cytomegalovirus (CMV). Infection caused by CMV leads to superinfection with other opportunistic or ganisms in transplant recipients

Diagnosis
Since in a large num ber of cases the diagnosis o f severe fungal infection is established only postmortem, the clinician must maintain a high index o f suspicion and, in the face of appropriate evidence, consider starting empirical therapy with antifungal agents [79, 80] . The relative value of the different techniques, such as open-lung biopsy, bronchoalveolar lavage, and fine-needle aspiration, for the diagnosis of pulmonary fungal infection in the immunocompromised host (reviewed in [42, 43, 48, 73, 81] ) has not been formally evaluated in solid-organ recipients; the guidelines estab lished for other types o f immunocompromised patients are followed and will not be discussed here.
The development of new diagnostic methods that detect fungal antigen in serum and other body fluids at an early stage of fungal infection has so far had little impact on the clinical management o f solid-organ recipients. The detection of Candida antigen in the serum of immunocompromised patients (bone marrow transplant recipients or neutropenic patients) and in burned patients has so far had relatively low utility [82] [83] [84] . The latex test has a sensitivity of 54% and a specificity of 29% [82] . The Cand-tec detection test (Ramco Laboratories, Houston) in neutropenic patients has a sensitiv ity of 76% and a specificity of 93% [83] . In one study of bone marrow recipients, the positive and negative predictive val ues of Candida antigen detection were 100% and 97%, respec tively [85] . With regard to solid-organ recipients, Candida antigen was detected in eight of nine liver transplant patients with deep fungal infection and in none of the 20 patients who were not infected [86] . The clinical usefulness o f Asper gillus antigen detection in serum is being studied, mainly in bone marrow recipients and neutropenic patients. Its sensitiv ity and specificity are 75% and 100%, respectively [87] , and its positive and negative predictive values for pulmonary and disseminated aspergillosis are --95% [88, 89] .
Surveillance Cultures
Surveillance cultures are routinely undertaken in some solid-organ transplantation programs; however, their predic tive value, especially in fungal infection, remains unknown. Heart-lung, pancreas, and liver recipients are often colonized with Candida organisms; even though most patients who de velop a deep candidal infection are known to have been pre viously colonized, many colonized patients do not develop infection. The clinical value of surveillance cultures for the early diagnosis of deep candidal infection has been studied primarily in bone marrow recipients. The results indicate a good negative predictive value but a poor positive predictive value for C. albicans infection [85, 90] as well as good nega tive and positive predictive values for infection with other species, such as C. tropical is [85] . In liver transplant recipi ents, colonization with C. albicans in three or more sites does not appear to correlate with deep fungal infection: surveil lance cultures were positive in eight of 11 cases in which deep candidal infection developed but also in eight of 16 cases in which it did not-for a sensitivity of 78% but a speci ficity of only 50% [86] . Strain typing by DNA fingerprinting has indicated that the isolate causing infection is previously present in the colonizing flora [70] .
Treatment
Treatment of deep fungal infections in solid-organ recipi ents does not differ significantly from that in other types of immunocompromised hosts, although special considerations apply. Except for candidiasis and aspergillosis, fungal infec tions (mucormycosis, cryptococcosis, blastomycosis, and his toplasmosis) are relatively uncommon and should be m an aged in solid-organ recipients as they are in other immuno compromised hosts (reviewed in [42, 43, [91] [92] [93] ). Here, we summarize recent developments in therapy for candidiasis and aspergillosis, and we discuss the implications o f these developments for solid-organ transplantation.
Amphotericin B. Intravenous amphotericin B has been the mainstay o f treatm ent for deep candidal infection, asper gillosis, and cryptococcosis [94, 95] . Although this agent is effective in certain cases, its use in solid-organ transplanta tion is associated with undesirable side effects. In addition to bone marrow toxicity (which may aggravate or be confused with that caused by azathioprine or CM V infection), nephro toxicity is common. This condition is reversible by means of drug discontinuation or salt loading in other immunosuppressed patients [96, 97] , but solid-organ transplant patients requiring treatm ent with amphotericin B may already have impaired renal function and may already be receiving a vari ety o f drugs (such as cyclosporine) that-by themselves or in association with amphotericin B-can potentiate renal toxic ity. The interaction o f cyclosporine and amphotericin B has been associated with acute renal failure [76, 98] , and ampho tericin B may increase plasma levels o f cyclosporine [99] . This situation is especially im portant in kidney recipients, who are more vulnerable than other types o f solid-organ re cipients to renal dysfunction caused by allograft rejection. Thus nephrotoxicity secondary to treatm ent with amphoteri cin B needs to be differentiated from that induced by drugs such as cyclosporine, by allograft rejection, and occasionally by CMV infection.
The liposomal form o f amphotericin B appears to have fewer adverse effects at equivalent doses and thus can be allowed to reach presumably much higher serum and tissue concentrations [100] . No difference between in vitro suscep tibility to conventional amphotericin B and that to the lipo somal drug has been found for the different fungal strains [101, 102] . Open trials o f liposomal amphotericin B in neu tropenic patients and bone marrow recipients show-in com parison with the conventional drug-a similar or improved efficacy profile with a lower incidence o f side effects in the treatment o f infections due to Candida and Aspergillus spe cies [100, [103] [104] [105] [106] [107] [108] [109] [110] ; in contrast, descriptions o f isolated cases o f cryptococcal meningitis in patients with AIDS indi cate that the efficacy o f liposomal amphotericin B is not ideal [111] . Its safety profile in solid-organ transplantation and its expected efficacy in the treatm ent o f severe infections caused by Aspergillus, Candida, and Cryptococcus species remain to be evaluated. Preliminary reports indicate that this agent may be clinically useful in some types o f solid-organ trans plantation ( [112, 113] and author's unpublished observa tions). Liposomal amphotericin B may be a valid alternative for the treatm ent o f candidal urinary tract infection [114] in recipients o f renal and pancreatic (bladder drainage) trans plants.
5-Fluorocytosine combined with amphotericin B for 6 weeks is indicated for the treatment of cryptococcal meningi tis [ 115, 116] , which-after candidiasis and aspergillosis-is the most common type o f fungal infection among organ transplant recipients. The role o f fluconazole as an alterna tive to this combination therapy is currently being evaluated. Ketoconazole, itraconazole, and fluconazole. Ketoconazole, an oral broad-spectrum antifungal drug, has little role in solid-organ transplantation since it is not indicated for the treatment of invasive candidiasis or aspergillosis in immuno compromised patients [92] . This drug is effective in therapy for North American mycoses (blastomycosis, coccidioido mycosis, and histoplasmosis), but these infections are not predominant among transplant recipients. Moreover, the use of ketoconazole in the treatment of the latter fungal infec tions in immunocompromised patients is associated with an increased rate o f relapse as compared with amphotericin B [117] . Ketoconazole can cause liver dysfunction [118] [119] [120] ; this complication is encountered especially often in the man agement o f liver transplant recipients. Ketoconazole also in teracts with cyclosporine, increasing the plasma levels o f the latter drug by blocking the cytochrome P-450 system or by displacing the protein-bound fraction [121] [122] [123] [124] .
Itraconazole, another oral imidazole, is active against Aspergillus species but exhibits poor CNS penetration (re viewed in [125] ). Itraconazole interacts with cyclosporine to a lesser degree than does ketoconazole [76] , although it has been reported to increase plasma levels o f cyclosporine [126] . In preliminary, unrandomized clinical trials, itracona zole has appeared to be somewhat efficacious against asper gillus infections in immunocompromised patients [94, 127, 128] . Studies comparing itraconazole with liposomal am photericin B in terms of safety and efficacy for the treatment of aspergillosis in solid-organ transplant recipients remain to be done.
Because o f its excellent pharmacokinetic properties, its low incidence o f side effects, and its minimal interference with cyclosporine, fluconazole is a potentially useful com pound in solid-organ transplantation. Unlike the other azoles, fluconazole has a low protein-binding capacity ( 11%), is excreted mainly via the kidneys, and effectively penetrates the CNS [129] . Its antifungal spectrum, both in vitro and in vivo, covers C. albicans and C. neoformans. Even though flu conazole exhibits poor in vitro activity against Aspergillus species, animal models o f disseminated aspergillosis show that this agent is somewhat effective in controlling this infec tion [130] [131] [132] . No clinical data yet support the use o f flu conazole in human aspergillosis. Studies o f surgical patients and o f immunocompromised patients (mainly those with AIDS) show fluconazole to be effective for the treatm ent of oral and esophageal candidiasis, cryptococcal meningitis, and deep-seated candidal infections [133] [134] [135] [136] [137] [138] . The safety and efficacy o f this agent in solid-organ transplantation have not been formally evaluated. One report on the administra tion o f fluconazole to two pancreas recipients and one kid ney recipient in whom nephrotoxicity was a major block to the use o f amphotericin B indicated that this drug was effec tive against invasive candidiasis (which developed in two pa tients), allowing the preservation o f the transplanted organ and causing no significant adverse reactions [139] . A major advantage o f fluconazole is its minimal interference with cyclosporine; fluconazole has only a very minor effect on the hepatic cytochrome P-450 system [140] [141] [142] , although in creased plasma levels o f cyclosporine have been reported with its use [143, 144] . One im portant issue in the treatment of candidal infection with fluconazole is that certain species, such as C. krusei, exhibit a low level o f susceptibility in vitro. Although experimental models indicate some efficacy of flu conazole against C. krusei [145] , emergence of this species after fluconazole treatm ent has been reported in immuno compromised patients [146] , Because C. krusei infections are not uncommon in neutropenic patients [69] and because the incidence o f infection caused by this species in solid-organ recipients is unknown, empirical treatm ent with fluconazole for a presumed candidal infection should be undertaken with caution.
Research on new antifungal compounds continues. Saperconazole, a triazole with potent activity against Aspergillus species in vitro and in immunosuppressed animal models [147, 148] , is in the preliminary stages o f development. The evaluation o f cilofungin, another experimental drug with ex cellent activity against Candida species [149] , has been dis continued because o f the development o f hepatocarcinoma in rodents during studies o f carcinogenesis (J. Albrecht, per sonal communication).
Immunotherapy complementing treatm ent with antifun gal drugs needs further evaluation. The activation o f macro phages in vitro by interferon y results in antifungal killing [150] . Although interferon y is potentially useful against fungal infection, its positive immunomodulatory role-with a subsequent increase in allograft rejection-is a source of concern [151] . Colony-stimulating factors, such as granulocyte-macrophage colony-stimulating factor, can boost the turnover and function o f monocytes and neutrophils [152 154] ; the role o f these factors in vivo in defense against fun gal infections needs to be evaluated in immunocompromised patients. Likewise, combinations of antifungal drugs with im munoglobulin preparations or antifungal monoclonal anti bodies may merit further study. Experimental models show enhanced efficacy when antibodies to Candida are linked to amphotericin B-carrying liposomes [155] .
Prophylaxis
Prophylaxis o f severe fungal infections should be a high priority in the management o f solid-organ transplant recipi ents. Risk factors for fungal infection in each type o f solid-or gan transplantation need to be identified. Those patients with specific risk factors should be monitored especially care fully, with a high index o f suspicion.
Protective isolation has not been as extensively studied for solid-organ recipients as for bone marrow recipients; in the latter patients this type of isolation-together with laminar airflow-reduces the incidence of severe infections, espe cially those caused by Aspergillus species [43, 72, 156, 157] . In one comparative study of renal transplantation, patients hospitalized in areas with high-efficiency particulate air (HEPA) filters had a lower incidence of invasive aspergillosis and of colonization with Aspergillus than did control patients (5% vs. 18% and 3% vs. 8%, respectively) [43] . Protective iso lation, as the sole prophylactic measure, failed to protect heart transplant recipients from the development o f a variety o f severe infections, including fungal infections [158] .
Most studies evaluating the safety and efficacy of antifun gal drug prophylaxis have involved bone marrow recipients rather than solid-organ recipients (reviewed in [156, 157] ). As has already been discussed, special risk factors and under lying pathogenic mechanisms make these two populations different. Nonetheless, transplantation centers have applied the experience gathered from bone marrow recipients and from patients with cancer and have introduced prophylactic regimens into their management programs for solid-organ recipients. Nystatin and amphotericin B are two nonabsorb able antifungal polymers that eradicate colonizing Candida from the human gastrointestinal tract. Even though the mini mal dose of nystatin reputed to eradicate yeasts from the digestive tract is 4.5 million IU/d, doses as high as 30 million IU /d have sometimes been clinically ineffective [159, 160] . Clearance of yeasts from the oropharynx appears to be easier than clearance from the lower gastrointestinal tract [161, 162] . In one study of liver transplantation, the administra tion of nystatin as part of a prophylactic program of selective bowel decontamination was associated with a low incidence of fungal infection, correlating with decreased candidal col onization in both the upper and the lower portions of the gastrointestinal tract [59] . Because this study was not ran domized, it is difficult to delineate the role o f nystatin; the incidence of gram-negative bacterial infections also de creased, and this change probably led to the administration of less antibacterial therapy. Oral amphotericin B gives better results than nystatin in leukemic patients and bone marrow recipients [163] . Doses of amphotericin B as high as 1,500 mg/d may be required to eradicate Candida species from the lower gastrointestinal tract [159, 164] ; however, both high and low prophylactic doses can fail [164, 165] .
Once more, the efficacy of oral agents such as nystatin and amphotericin B in solid-organ transplantation remains to be evaluated in prospective randomized studies, and the data available supporting the use of these agents come from stud ies of other immunocompromised patients. Intravenous ad ministration of amphotericin B to febrile neutropenic pa tients who are not responding to antibacterial agents [79, 80] needs to be assessed individually in solid-organ transplant recipients, with special consideration of the time of onset of fever after transplantation and o f specific underlying risk fac tors. The use o f amphotericin B as a prophylactic agent in liver transplantation is currently being analyzed [166] .
As prophylaxis o f candidal infections, ketoconazole has been evaluated in leukemic patients and bone marrow trans plant recipients but not in solid-organ recipients [163, 164, [167] [168] [169] [170] . Its need for an acidic gastric pH for absorption and its interaction with cyclosporine make ketoconazole less than ideal for prophylaxis in these groups o f patients. Clotri mazole troches have been reported to be effective in prevent ing oral candidal colonization and infection in renal trans plant recipients [171] .
Fluconazole, whose use is in many respects more conve nient than that o f ketoconazole, may be superior for prophy laxis against candidal and cryptococcal infection in solidorgan transplant recipients [172, 173] . Its efficacy in pre venting relapse and dissemination o f cryptococcal meningi tis in patients with AIDS [174, 175] may be of practical importance in certain isolated cases o f solid-organ transplan tation. Randomized trials are under way to evaluate the safety and efficacy o f fluconazole in the prevention of deep fungal infections in orthotopic liver transplantation. Once more, the emergence o f Candida species resistant to flucona zole (e.g., C. krusei) is o f great concern in any clinical situa tion in which this drug is being administered prophylactically for prolonged periods to patients with multiple risk factors for severe candidal infections [176] . In a recent randomized, placebo-controlled study o f bone marrow recipients, flucon azole was effective for prophylaxis o f infections due to all Candida species except C. krusei [177] . However, the in creased incidence o f C. krusei infections did not result in increased mortality.
Itraconazole has not been evaluated in the prophylaxis of aspergillus infections in solid-organ transplant recipients. However, studies in progress are assessing the efficacy o f this agent in the prophylaxis o f infections due to Candida and Aspergillus species in cancer patients [178, 179] .
New applications o f established drugs (e.g., the intranasal administration o f amphotericin B) are being studied in other types o f immunocompromised patients [43, 156, 165, 180] and will need to be evaluated in solid-organ transplant recipi ents as well. Moreover, the administration o f amphotericin B in an aerosol formulation merits further study. Preliminary assessments in experimental models and in granulocyto penic patients suggest that the latter route o f administration may be effective in the prophylaxis o f aspergillus infection [181, 182] . Other experimental antifungal agents are being evaluated for prophylaxis in animal models [183] . The use of prophylactic immunoglobulin in solid-organ transplantation appears to decrease the incidence o f fungal infection. In one study o f renal transplant recipients with high titers of anti body to CMV, immunoglobulin administration decreased the incidence o f fungal infection [22] ; results were similar in a study o f bone marrow recipients [78] .
Conclusion
In summary, the incidence and severity of fungal infec tions may decrease in the future as the result of a knowledge of the specific risk factors for each type of transplant recipi ent; a high index o f suspicion of fungal infection, with the application of rapid and aggressive diagnostic methods; and the use of highly specific antifungal prophylactic agents that cause little toxicity and that interact minimally with other drugs given to transplant recipients. 
